|
|
| | ITX-5061 HCl Basic information |
| Product Name: | ITX-5061 HCl | | Synonyms: | ITX-5061 HCl;ITX-5061;ITX-5061 hydrochloride
(ITX5061);ITX-5061 hydrochloride;ITX506 HCl;N-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride , ITX5061;N-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride | | CAS: | 1252679-52-9 | | MF: | C30H38ClN3O7S | | MW: | 620.16 | | EINECS: | | | Product Categories: | | | Mol File: | 1252679-52-9.mol |  |
| | ITX-5061 HCl Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 83.3 mg/mL (134.32 mM) | | form | Solid | | color | Light yellow to light brown |
| | ITX-5061 HCl Usage And Synthesis |
| Uses | ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). | | in vivo | ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). Treatment of ITX5061 (30 mg/kg/day) for mice results in a 50% increase in HDL-C levels compare to baseline. ApoA-I levels are moderately (+15 %) but significantly increased in ITX5061-treated HuAITg mice, compare to mice receive vehicle. ITX5061 significantly decreases HDL-CE catabolism with an FCR of 1.86±0.40 pools/d vs 2.47±0.26 pools/d in the control group (P<0.05), while calculated production rates are identical in both groups (129±24 μg/g/d vs 129±16 μg/g/d). Moreover, accumulation of [3H] CE in the liver is significantly lower in ITX5061-treated mice indicating that increased HDL-CE levels are due to reduced uptake by the liver[1]. | | References | [1] Masson D, et al. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2054-60. DOI:10.1161/ATVBAHA.109.191320 |
| | ITX-5061 HCl Preparation Products And Raw materials |
|